From Name:
From Email:
To Name:
To Email:

Optional Message:


University of Minnesota heads for 'patent cliff'

from The Minnesota Daily

The University of Minnesota's research community will be out of a big chunk of spending money as patents on a blockbuster HIV drug expire. The school has made more than $350 million off a drug invented on campus in the 1980s, but as the patents expire, those royalties are dwindling toward zero. And that means fewer investments into research. The HIV drug Ziagen was a prime example of what commercializing research — called "tech transfer" — can mean for a university. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063